TRHC · Tabula Rasa Healthcare, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $90.04M | $88.28M | - | $77.10M | $72.60M | $67.11M | - | $86.59M | $82.31M | $76.68M |
| Cost of Revenue | $67.51M | $67.52M | - | $60.23M | $56.63M | $52.72M | - | $61.16M | $57.26M | $54.03M |
| Gross Profit | $22.53M | $20.75M | - | $16.87M | $15.97M | $14.39M | - | $25.42M | $25.05M | $22.65M |
| R&D | $1.78M | $1.28M | - | $4.02M | $3.24M | $3.96M | - | $4.98M | $5.92M | $3.99M |
| SG&A | $17.60M | $16.58M | - | $27.92M | $15.15M | $15.88M | - | $16.87M | $19.95M | $17.54M |
| Total Operating Expenses | $31.56M | $26.91M | - | $40.52M | $26.05M | $32.30M | - | $40.17M | $43.81M | $39.40M |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($9.03M) | ($6.16M) | - | ($23.65M) | ($10.09M) | ($17.91M) | - | ($14.75M) | ($18.77M) | ($16.75M) |
| Interest Expense | - | - | - | - | - | - | - | $2.23M | $2.18M | $2.55M |
| Income Tax | $133.0K | $105.0K | - | ($7.0K) | $159.0K | $216.0K | - | $134.0K | $133.0K | $199.0K |
| Net Income | ($9.85M) | ($15.90M) | - | ($40.06M) | ($49.61M) | ($28.19M) | - | ($17.11M) | ($21.08M) | ($19.49M) |
| EPS - Basic | ($0.38) | ($0.63) | - | ($1.65) | ($2.07) | ($0.85) | - | ($0.99) | ($0.66) | - |
| EPS - Diluted | ($0.38) | ($0.63) | - | ($1.65) | ($2.07) | ($0.85) | - | ($0.73) | ($0.66) | - |
Balance Sheet
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $62.81M | $67.19M | $70.02M | $80.78M | $26.52M | $14.45M | $9.67M | $11.35M | $12.27M | $16.90M |
| Accounts Receivable | $18.61M | $19.14M | $19.25M | $18.96M | $20.32M | $22.44M | $34.05M | $31.74M | $35.26M | $29.36M |
| Inventory | $8.66M | $7.39M | $6.57M | $5.74M | $5.80M | $4.90M | $5.44M | $5.13M | $4.87M | $4.08M |
| Accounts Payable | $20.62M | $21.91M | $19.46M | $14.69M | $15.80M | $9.54M | $13.18M | $13.02M | $10.27M | $6.73M |
| Current Assets | $146.68M | $142.95M | $170.26M | $179.84M | $266.30M | $289.12M | $89.89M | $88.25M | $89.75M | $84.88M |
| Total Assets | $355.94M | $355.60M | $384.15M | $403.85M | $484.47M | $506.80M | $499.42M | $500.98M | $503.89M | $502.59M |
| Current Liabilities | $93.69M | $86.33M | $102.08M | $98.06M | $154.13M | $76.20M | $73.92M | $65.32M | $65.67M | $61.55M |
| Long-term Debt | - | - | - | $320.30M | $319.96M | - | - | - | - | - |
| Total Liabilities | $434.02M | $426.46M | $441.18M | $435.50M | $491.15M | $470.57M | $443.66M | $433.73M | $428.12M | $418.97M |
| Stockholders' Equity | ($78.08M) | ($70.86M) | ($57.03M) | ($31.65M) | ($6.68M) | $36.23M | $55.76M | $67.25M | $75.78M | $83.62M |
| Retained Earnings | ($433.61M) | ($423.75M) | ($407.86M) | ($378.21M) | ($338.15M) | ($288.54M) | ($260.35M) | ($238.98M) | ($221.87M) | ($200.78M) |
Cash Flow
| Line item | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($8.75M) | - | - | - | ($15.73M) | - | - | - | ($4.08M) |
| Investing Cash Flow | - | $180.0K | - | - | - | ($8.97M) | - | - | - | ($6.38M) |
| Financing Cash Flow | - | ($403.0K) | - | - | - | $27.41M | - | - | - | $2.12M |
| CapEx | - | $719.0K | - | - | - | $217.0K | - | - | - | $522.0K |
| Free Cash Flow | - | ($9.47M) | - | - | - | ($15.95M) | - | - | - | ($4.60M) |
Ratios
| Metric | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 25.0% | 23.5% | - | 21.9% | 22.0% | 21.4% | - | 29.4% | 30.4% | 29.5% |
| Operating margin | -10.0% | -7.0% | - | -30.7% | -13.9% | -26.7% | - | -17.0% | -22.8% | -21.8% |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | -10.9% | -18.0% | - | -52.0% | -68.3% | -42.0% | - | -19.8% | -25.6% | -25.4% |
| Free cash flow margin | - | -10.7% | - | - | - | -23.8% | - | - | - | -6.0% |
| FCF / Net income | - | 0.60 | - | - | - | 0.57 | - | - | - | 0.24 |
| R&D / Revenue | 2.0% | 1.4% | - | 5.2% | 4.5% | 5.9% | - | 5.8% | 7.2% | 5.2% |
| SG&A / Revenue | 19.5% | 18.8% | - | 36.2% | 20.9% | 23.7% | - | 19.5% | 24.2% | 22.9% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -2.8% | -4.5% | - | -9.9% | -10.2% | -5.6% | - | -3.4% | -4.2% | -3.9% |
| Return on equity | 12.6% | 22.4% | - | 126.6% | 742.3% | -77.8% | - | -25.4% | -27.8% | -23.3% |
| Return on invested capital | - | - | - | -6.5% | -2.5% | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.57 | 1.66 | 1.67 | 1.83 | 1.73 | 3.79 | 1.22 | 1.35 | 1.37 | 1.38 |
| Quick ratio | 1.47 | 1.57 | 1.60 | 1.78 | 1.69 | 3.73 | 1.14 | 1.27 | 1.29 | 1.31 |
| Cash ratio | 0.67 | 0.78 | 0.69 | 0.82 | 0.17 | 0.19 | 0.13 | 0.17 | 0.19 | 0.27 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | -10.12 | -47.88 | - | - | - | - | - |
| Debt / Assets | - | - | - | 0.79 | 0.66 | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | -6.6x | -8.6x | -6.6x |
| Equity multiplier | -4.56 | -5.02 | -6.74 | -12.76 | -72.49 | 13.99 | 8.96 | 7.45 | 6.65 | 6.01 |
| Liabilities / Assets | 1.22 | 1.20 | 1.15 | 1.08 | 1.01 | 0.93 | 0.89 | 0.87 | 0.85 | 0.83 |
| Efficiency | ||||||||||
| Asset turnover | 0.25 | 0.25 | - | 0.19 | 0.15 | 0.13 | - | 0.17 | 0.16 | 0.15 |
| Inventory turnover | 7.80 | 9.14 | - | 10.50 | 9.77 | 10.76 | - | 11.93 | 11.77 | 13.23 |
| Days sales outstanding | 75d | 79d | - | 90d | 102d | 122d | - | 134d | 156d | 140d |
| Days inventory outstanding | 47d | 40d | - | 35d | 37d | 34d | - | 31d | 31d | 28d |
| Days payable outstanding | 112d | 118d | - | 89d | 102d | 66d | - | 78d | 65d | 45d |
| Cash conversion cycle | 11d | 1d | - | 36d | 38d | 90d | - | 87d | 122d | 122d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 24.0% | 31.5% | - | -11.0% | -11.8% | -12.5% | - | 22.8% | 7.1% | 5.3% |
| Revenue CAGR (3y) | 5.4% | 6.6% | - | 1.3% | -1.6% | 3.3% | - | 16.7% | 40.9% | 39.9% |
| Revenue CAGR (5y) | 25.1% | 25.8% | - | 18.3% | 19.6% | 19.4% | - | 37.0% | - | - |
| Gross profit growth (YoY) | 41.1% | 44.2% | - | -33.7% | -36.3% | -36.5% | - | 19.6% | -0.4% | -8.5% |
| Operating income growth (YoY) | 10.5% | 65.6% | - | -60.4% | 46.2% | -6.9% | - | 21.1% | -84.9% | -26.9% |
| Net income growth (YoY) | 80.1% | 43.6% | - | -134.1% | -135.3% | -44.6% | - | 20.7% | -47.3% | -35.0% |
| EPS growth (YoY) | 81.6% | 25.9% | - | -126.0% | -213.6% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | 40.6% | - | - | - | -246.8% | - | - | - | -194.9% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -1068.3% | - | - | - | - | -56.7% | -66.9% | -59.2% | -56.3% | -53.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Business segments
$331.26M totalCarevention Healthcare$248.01M · 74.9%
Medwise Healthcare$83.25M · 25.1%
Product / service
$662.04M totalProduct$190.07M · 28.7%
Pace Product$189.59M · 28.6%
Service$141.19M · 21.3%
Pace Solutions$58.42M · 8.8%
Software Subscription And Services$44.27M · 6.7%
Medication Safety Services$38.50M · 5.8%
Peer comparison
Same SIC group: Services-Business Services, NEC
Comparing Tabula Rasa HealthCare against the 5 most active filers in the same SIC group.